Overview

ITI-007 (Lumateperone Tosylate) for Schizophrenia

Status:
Terminated
Trial end date:
2020-09-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to offer open label ITI-007 treatment to patients who poorly respond or poorly tolerate approved medications.
Phase:
Phase 2
Details
Lead Sponsor:
New York State Psychiatric Institute
Collaborator:
Intra-Cellular Therapies, Inc.